The optimal strategy for relapse detection after curative treatment of large-cell B lymphoma is still controversial.
Our findings suggest that the relapse is most commonly suspected by the patient or the clinician and it is rarely detected only by imaging.
The risk of surveillance are not fully justified as it probably implies exposure to unnecessary radiation, which has been linked to cancer development.
59% of our patients had cumulative effective dose greater than 100 mSv due to surveillance CT, the threshold often considered for significant risk.